top of page


  1. Arenas M, Sabater S, Hernández V, Rovirosa A, Lara PC, Biete A, Panés J. Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved. Strahlenther Onkol. 2012 Nov;188(11):975-81. doi: 10.1007/s00066-012-0170-8. Epub 2012 Aug 22.

  2. Rödel F, Fournier C, Wiedemann J, Merz F, Gaipl US, Frey B, Keilholz L, Seegenschmiedt MH, Rödel C, Hehlgans S. Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases. Front Immunol. 2017 May 3;8:519. doi: 10.3389/fimmu.2017.00519. eCollection 2017.

  3. Frey B, Hehlgans S, Rödel F, Gaipl US. Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases. Cancer Lett. 2015 Nov 28;368(2):230-7. doi: 10.1016/j.canlet.2015.04.010.

  4. Rödel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol. 2007 Jun;83(6):357-66.

  5. Leer JW, van Houtte P, Seegenschmiedt H. Radiotherapy of non-malignant disorders: where do we stand? Radiother Oncol. 2007 May;83(2):175-7.

  6. McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, Taylor RE. Radiotherapy for  benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol. 2015;88(1056):20150405. doi: 10.1259/bjr.20150405.

  7. Reichl B, Block A, Schäfer U, Bert C, Müller R, Jung H, Rödel F; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol.  2015 Sep;191(9):701-9. doi: 10.1007/s00066-015-0865-8.

  8. Ott OJ, Niewald M, Weitmann HD, Jacob I, Adamietz IA, Schaefer U, Keilholz L,  Heyd R, Muecke R; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO guidelines for the radiotherapy of non-malignant disorders. Part  II: Painful degenerative skeletal disorders. Strahlenther Onkol. 2015 Jan;191(1):1-6. doi: 10.1007/s00066-014-0757-3.

  9. Seegenschmiedt MH, Micke O, Niewald M, Mücke R, Eich HT, Kriz J, Heyd R; German Cooperative Group on Radiotherapy of Benign Diseases (GCG-BD). DEGRO guidelines for the radiotherapy of non-malignant disorders : part III: hyperproliferative disorders. Strahlenther Onkol. 2015 Jul;191(7):541-8. doi: 10.1007/s00066-015-0818-2.

  10. Reinartz G, Eich HT, Pohl F; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders. Strahlenther Onkol. 2015 Apr;191(4):295-302. doi: 10.1007/s00066-014-0789-8.

  11. Seegenschmiedt MH, Micke O, Muecke R; German Cooperative Group on Radiotherapy for Non-malignant Diseases (GCG-BD). Radiotherapy for non-malignant  disorders: state of the art and update of the evidence-based practice guidelines. Br J Radiol. 2015 Jul;88(1051):20150080. doi: 10.1259/bjr.20150080.

  12. Seegenschmiedt MH, Micke O, Willich N. Radiation therapy for nonmalignant diseases in Germany. Current concepts and future perspectives. Strahlenther Onkol. 2004 Nov;180(11):718-30.

  13. Taylor RE, Hatfield P, McKeown SR, Prestwich RJ, Shaffer R. Radiotherapy for Benign Disease: Current Evidence, Benefits and Risks. Clin Oncol (R Coll Radiol). 2015 Aug;27(8):433-5. doi: 10.1016/j.clon.2015.01.009.

  14. Montero Luis A, Hernanz de Lucas R, Hervás Morón A, Fernández Lizarbe E, Sancho García S, Vallejo Ocaña C, Polo Rubio A, Ramos Aguerri A. Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases.  Clin Transl Oncol. 2008 Jun;10(6):334-46.

  15. Pakos EE, Ioannidis JP. Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):888-95.]

bottom of page